Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286234 · ClinicalTrials.gov registry record · Phase 4
Niacin, N-3 Fatty Acids and Insulin Resistance
A Phase 4 study, sponsored by University of South Dakota.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT00286234 is a Phase 4 study that has completed, run by University of South Dakota. The registered enrollment target is 68 participants.
The verdict
NCT00286234, a Phase 4 study, has completed, sponsored by University of South Dakota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
This research study is being conducted to test the effects of two drugs on blood lipids (cholesterol and triglycerides) and blood sugar (glucose) levels in patients with diabetes or "pre-diabetes" (both of which have a condition called "insulin-resistance"). These products are Niaspan (extended release nicotinic acid) and Omacor (omega-3 acid ethyl esters). We hypothesize that the combination of Niaspan and Omacor will reduce serum triglyceride levels, increase HDL-cholesterol levels and do so without altering glucose levels.
Interventions
- DRUG placebo
- DRUG omega-3 acid ethyl esters
- DRUG extended release niacin
- DRUG combined treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286234
The ClinicalTrials.gov registry entry for NCT00286234 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Dakota, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00286234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00286234 about?
NCT00286234 is a clinical study titled "Niacin, N-3 Fatty Acids and Insulin Resistance". This research study is being conducted to test the effects of two drugs on blood lipids (cholesterol and triglycerides) and blood sugar (glucose) levels in patients with diabetes or "pre-diabetes" (both of which have a condition called "insulin-resistance"). These products are Niaspan (extended rele...
What is the current status of trial NCT00286234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2007-10. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00286234?
The interventions under investigation include: placebo (DRUG), omega-3 acid ethyl esters (DRUG), extended release niacin (DRUG), combined treatment (DRUG).
Who is sponsoring clinical trial NCT00286234?
This trial is sponsored by University of South Dakota, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.